Acetyl zingerone

Acetyl zingerone 是一种 Zingerone (MS-X11849) 类似物,可下调 ROS 代谢相关基因、成纤维细胞衰老相关基因、角质形成细胞分化相关基因以及 IL-17A 靶基因的表达,抑制 MMP-1、MMP-3、MMP-12 的活性以及 NLRP3 炎症小体激活、细胞焦亡 (pyroptosis)、铁死亡 (ferroptosis)、软骨破坏和 UVA 诱导的环丁烷嘧啶二聚体形成,同时上调胶原蛋白、蛋白聚糖、细胞外基质糖蛋白、Notch 通路以及 GPX4 基因的表达,激活 Nrf2 与 HO-1,诱导细胞外基质合成以及 PINK1/Parkin 介导的线粒体自噬 (mitophagy),促进软骨细胞存活,缓解小鼠的骨关节炎进展,并可用于皮肤衰老、炎症性皮肤病、骨关节炎、黑色素瘤以及非黑色素瘤皮肤癌的相关研究。
产品编号: MS-D67280 纯度: 99.34% CAS No.: 30881-23-3 分子式: C13H16O4 分子量: 236.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Acetyl zingerone 是一种 Zingerone (MS-X11849) 类似物,可下调 ROS 代谢相关基因、成纤维细胞衰老相关基因、角质形成细胞分化相关基因以及 IL-17A 靶基因的表达,抑制 MMP-1、MMP-3、MMP-12 的活性以及 NLRP3 炎症小体激活、细胞焦亡 (pyroptosis)、铁死亡 (ferroptosis)、软骨破坏和 UVA 诱导的环丁烷嘧啶二聚体形成,同时上调胶原蛋白、蛋白聚糖、细胞外基质糖蛋白、Notch 通路以及 GPX4 基因的表达,激活 Nrf2 与 HO-1,诱导细胞外基质合成以及 PINK1/Parkin 介导的线粒体自噬 (mitophagy),促进软骨细胞存活,缓解小鼠的骨关节炎进展,并可用于皮肤衰老、炎症性皮肤病、骨关节炎、黑色素瘤以及非黑色素瘤皮肤癌的相关研究。

生物实验数据

生物活性 Acetyl zingerone is a Zingerone (MS-X11849) analog that downregulates the expression of ROS metabolism-related genes, fibroblast senescence-related genes, keratinocyte differentiation-related genes, and IL-17A target genes, inhibits the activities of MMP-1, MMP-3, and MMP-12 as well as NLRP3 inflammasome activation, pyroptosis, ferroptosis, cartilage destruction, and UVA-induced cyclobutane pyrimidine dimer formation, while upregulating the expression of collagen, proteoglycans, extracellular matrix glycoproteins, the Notch pathway, and GPX4, activating Nrf2 and HO-1, inducing extracellular matrix synthesis and PINK1/Parkin-mediated mitophagy, promoting chondrocyte survival, alleviating osteoarthritis progression in mice, and serving as a potential agent for research on skin aging, inflammatory skin diseases, osteoarthritis, melanoma, and non-melanoma skin cancer.
体外研究
(In Vitro)

Acetyl zingerone 可改变重组人表皮中的基因表达,上调核心基质组、Notch 及 ERK1/ERK2 通路基因,同时下调炎症相关、TGF-β 信号通路及 AP-1/NF-κB 相关基因。
Acetyl zingerone (10-200 µg/mL; 6 day) 可呈剂量依赖性地提高培养的人皮肤成纤维细胞中单位细胞密度下的细胞外基质蛋白丰度。
Acetyl zingerone (10 µL/cm2; 每日 1 次,连续 4 天) 可使体外人面部皮肤活检样本的真皮胶原蛋白含量增加 2 倍。
Acetyl zingerone (从将 0.1 g AZ 溶解于 1 mL DMSO 制备的储备液开始进行 1:1 系列稀释;10 min (MMP-1, MMP-3); 15 min (MMP-12)) 可在无细胞实验中抑制 MMP-1、MMP-3 和 MMP-12 的活性,其中对 MMP-12 的抑制效力最强 (IC50 = 0.255 mg),其次是 MMP-3 (IC50 = 0.505 mg) 和 MMP-1 (IC50 = 1.065 mg)。
Acetyl zingerone 可逆转重组人表皮中与成纤维细胞衰老、角质形成细胞分化及 IL-17A 刺激相关的基因表达模式。
Acetyl zingerone (25-200 μM; 2-48 h) 对 ATDC5 软骨细胞有保护作用,可使其免受 LPS (MS-X54539)+ ATP (MS-D18391) 诱导的细胞毒性损伤并恢复增殖能力。
Acetyl zingerone (100 μM; 24 h) 可通过减轻细胞膜损伤、抑制 NLRP3 炎症小体活化及下游焦亡相关蛋白的表达,抑制 LPS + ATP 诱导的 ATDC5 软骨细胞焦亡。
Acetyl zingerone (100 μM; 24 h) 可通过降低 ROS/mtROS 生成、恢复线粒体膜电位与结构完整性,减轻 LPS + ATP 诱导的 ATDC5 软骨细胞线粒体损伤。
Acetyl zingerone (100 μM; 24 h pretreatment, 24 h LPS + ATP induction) 可激活经 LPS + ATP 处理的 ATDC5 软骨细胞中由 PINK1/Parkin 介导的线粒体自噬。
Acetyl zingerone (25-100 μM; 24-48 h) 提升经 IL-1β 处理的原代大鼠软骨细胞的存活率,恢复细胞的增殖能力。
Acetyl zingerone (25-100 μM; 24 h) 可通过上调聚集蛋白聚糖与 COL2A1、下调基质降解酶及炎性因子,维持经 IL-1β 处理的原代大鼠软骨细胞与小鼠 ATDC5 成软骨细胞的 ECM 稳态。
Acetyl zingerone (25-100 μM; 24 h) 可通过上调 Notch1 和 SOCS3、降低活化型 caspase-3 水平,抑制 IL-1β 诱导的经 IL-1β 处理的原代大鼠软骨细胞及小鼠 ATDC5 软骨发生细胞凋亡。
Acetyl zingerone (25-100 μM; 24 h) 可减少 IL-1β 诱导的原代大鼠软骨细胞内 ROS 的累积。
Acetyl zingerone (100 μM; 24 h) 可通过提升 GSH 水平、降低 MDA 水平、稳定线粒体结构以及上调 GPX4,激活 Nrf2/HO-1 通路,抑制 IL-1β 诱导的原代大鼠软骨细胞和小鼠 ATDC5 软骨生成细胞铁死亡。
Acetyl zingerone (25 µg/mL; 1-6 h post-UVA irradiation) 可显著降低 C57BL/6 小鼠黑素细胞在 UVA 照射后最初 2 小时内的暗态环丁烷嘧啶二聚体 (dark-CPD) 形成,照射后 1 小时时抑制率约达 82%,且不会损伤 DNA 修复功能或细胞活力。
Acetyl zingerone (25-50 µg/mL; 20 min pre-incubation prior to 25 min UVA irradiation) 可呈剂量依赖性地降低 UVA 诱导的人正常新生儿表皮角质形成细胞内 ROS 生成,降幅分别为 35% 和 46%。

ELISA Assay

Cell Line: Cultured human dermal fibroblasts
Concentration: 0, 10, 25, 50, 100, 200 µg/mL
Incubation Time: 6 day
Result: Increased protein abundance per unit cell density (P < 0.05) in a dose-dependent manner for type I, IV, and VI collagens; fibromodulin; transforming growth factor-β; fibronectin; TIMP-1; and vimentin.
Showed greater abundance with higher AZ concentrations, with significant differences from control observed at specific doses (e.g., type I collagen at 100 µg/mL, type IV collagen at 50 and 100 µg/mL).

Cell Viability Assay

Cell Line: ATDC5 chondrocytes
Concentration: 25, 50, 100, 200 μM
Incubation Time: 24 h, 48 h (co-treatment with LPS + ATP); 24 h (treatment with LPS + ATP), 2 h (EdU (MS-P82191) incubation)
Result: Shows no cytotoxicity at concentrations below 100 μM.
Significantly reduces cell viability at 200 μM after 24 h and 48 h.
Mitigates LPS + ATP-induced cytotoxicity, with 100 μM producing the most pronounced improvement in cell viability.
Reverses LPS + ATP-induced inhibition of chondrocyte proliferation, with 100 μM being the most effective concentration.

Cell Autophagy Assay

Cell Line: ATDC5 chondrocytes
Concentration: 100 μM
Incubation Time: 24 h pretreatment, followed by 24 h LPS + ATP induction
Result: Significantly increases the expression of PINK1, Parkin, and LC3-II, and decreases p62 expression in LPS + ATP-treated chondrocytes.
Enhances PINK1 and Parkin expression, which is suppressed by chloroquine (CQ) via immunofluorescence.
Increases co-localization of Parkin and LC3B with mitochondria, enhances autolysosome formation, and promotes mitophagic clearance of damaged mitochondria; these effects are attenuated by CQ.
Reduces LPS + ATP-induced ROS and mtROS production, an effect reversed by CQ.

Apoptosis Analysis

Cell Line: primary rat chondrocytes, mouse ATDC5 chondrogenic cells
Concentration: 25, 50 and 100 μM
Incubation Time: 24 h
Result: Reduced IL-1β-induced apoptosis (lower early + late apoptotic cell proportion), increased cell number, upregulated Notch1 and SOCS3 expression, and decreased the cleaved caspase-3/caspase-3 ratio compared with the IL-1β-treated group.
Flow cytometry confirmed the anti-apoptotic effect at 100 μM, while crystal violet staining and western blot showed dose-dependent effects at 25, 50, and 100 μM.
Produced similar results in mouse ATDC5 cells.

Western Blot Analysis

Cell Line: primary rat chondrocytes
Concentration: 100 μM
Incubation Time: 24 h
Result: Upregulated Nrf2, HO-1, and GPX4 expression compared with the IL-1β-treated group.
Had its protective effect on GPX4 expression abolished by Nrf2 or HO-1 inhibitors, which exacerbated IL-1β-induced GPX4 suppression.

ELISA Assay

Cell Line: C57BL/6 mouse melanocytes
Concentration: 25 µg/mL
Incubation Time: 1, 2, 4, 6 h post-UVA irradiation
Result: Significantly reduced dark-CPD formation within the first 2 h post-irradiation, with an ~82% reduction observed after 1 h compared to controls.
Matched control CPD levels by 6 h post-irradiation, indicating no interference with DNA repair.
Left cell viability unaffected.
体内研究
(In Vivo)

Acetyl zingerone (1 mg/kg;关节腔内注射;每周 2 次;持续 8 周) 可通过促进 PINK1/Parkin 介导的线粒体自噬、抑制软骨细胞焦亡、减轻软骨损伤及恢复软骨下骨重塑,缓解内侧半月板失稳模型 (DMM) 诱导小鼠的骨关节炎进展。

Animal Model: C57BL/6 J (male, 8-week-old, DMM surgery-induced osteoarthritis)
Dosage: 1 mg/kg
Administration: intra-articular injection; twice a week; 8 weeks
Result: Significantly reduced calcified menisci and bone remnants compared to the DMM-only group.
Normalized subchondral bone microarchitecture parameters, increasing bone volume/tissue volume (BV/TV) and trabecular thickness (Tb.Th) relative to the DMM-only group.
Reduced cartilage loss and proteoglycan depletion, lowering Osteoarthritis Research Society International (OARSI) scores compared to the DMM-only group.
Decreased immunohistochemical staining of pyroptosis-related protein NLRP3 and matrix-degrading protein MMP13 in cartilage tissues relative to the DMM-only group.
Increased immunohistochemical staining of mitophagy-related proteins Parkin and LC3B, as well as matrix-synthesizing protein Collagen II, in cartilage tissues relative to the DMM-only group.
性状 固体
颜色 White to off-white

化学信息

分子量 236.26
分子式 C13H16O4
CAS No. 30881-23-3

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (423.26 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.2326 mL21.1631 mL42.3263 mL105.8156 mL
5 mM0.8465 mL4.2326 mL8.4653 mL21.1631 mL
10 mM0.4233 mL2.1163 mL4.2326 mL10.5816 mL
15 mM0.2822 mL1.4109 mL2.8218 mL7.0544 mL
20 mM0.2116 mL1.0582 mL2.1163 mL5.2908 mL
25 mM0.1693 mL0.8465 mL1.6931 mL4.2326 mL
30 mM0.1411 mL0.7054 mL1.4109 mL3.5272 mL
40 mM0.1058 mL0.5291 mL1.0582 mL2.6454 mL
50 mM0.0847 mL0.4233 mL0.8465 mL2.1163 mL
60 mM0.0705 mL0.3527 mL0.7054 mL1.7636 mL
80 mM0.0529 mL0.2645 mL0.5291 mL1.3227 mL
100 mM0.0423 mL0.2116 mL0.4233 mL1.0582 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础